Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company achieved a revenue of 1.203 billion yuan in 2024, reflecting a growth of 14.75%, with a net profit attributable to shareholders of 254 million yuan, up by 15.95% [4][10]. - The company’s plasma collection volume increased steadily, reaching 562 tons in 2024, a year-on-year growth of 8.7% [5]. - The company is expanding its product range, having obtained a drug registration certificate for a new product, and is advancing its pipeline with new products in clinical trials [5]. - The life sciences park is showing industrial cluster effects, with rental income from the property business soaring by 250.44% in 2024 [6]. - Revenue projections for 2025-2027 are estimated at 1.288 billion, 1.415 billion, and 1.572 billion yuan respectively, with net profits expected to be 278 million, 317 million, and 369 million yuan [7][10]. Company Overview - The latest closing price of the company's stock is 27.88 yuan, with a total market capitalization of 6.3 billion yuan [3]. - The company has a debt-to-asset ratio of 31.9% and a price-to-earnings ratio of 24.94 [3].

Core Viewpoint - The blood products industry is experiencing a significant divergence in performance among companies, with some reporting growth while others face declines in revenue and profit [1][2]. Group 1: Company Performance in 2024 - Shanghai Laisai (002252) and Tiantan Biological (600161) reported revenue growth of 2.67% and 16.44% respectively, with net profits increasing by 23.25% and 39.58% [1]. - Hualan Biological (002007), Boya Biological (300294), and Bohui Innovation (300318) experienced revenue declines of 18.02%, 34.58%, and 18.53% respectively, while Hualan's net profit fell by 26.57% [1]. - Bohui Innovation managed to turn a profit with a net profit of 0.09 billion yuan, compared to a loss in the previous year [1]. Group 2: Q1 2025 Performance - In Q1 2025, Tiantan Biological, Hualan Biological, and Boya Biological continued to show revenue growth, while Shanghai Laisai, Tiantan Biological, and Paillin Biological saw revenue declines of 2.45%, 0.57%, and 14% respectively [1]. - Hualan Biological's net profit increased by 19.62%, while Shanghai Laisai and Tiantan Biological reported net profit declines of 25.2% and 22.9% respectively [1]. - The decline in profits for Tiantan Biological was attributed to a decrease in product prices that outweighed the benefits of increased sales volume [1]. Group 3: Market Dynamics - The blood products market is expected to maintain stable growth in 2024, with significant competition in the human albumin market due to increased imports [2][3]. - The cancellation of certain medical insurance restrictions is expected to release market demand for coagulation factor products, contributing to their growth [2]. - The overall price trend for blood products is declining, influenced by increased competition and supply exceeding demand for certain products [3]. Group 4: Industry Consolidation - The blood products industry is characterized by high entry barriers, with fewer than 30 companies currently operating due to strict regulations on blood product production [6][7]. - Recent mergers and acquisitions are expected to enhance industry concentration, with leading companies gaining competitive advantages through resource acquisition [6][7]. - Companies like Tiantan Biological and Shanghai Laisai have made significant acquisitions to expand their production capabilities and market presence [7]. Group 5: Market Size and Growth Projections - The blood products market in China reached a scale of 600 billion yuan in 2024, with projections to grow to 780 billion yuan by 2027, reflecting a compound annual growth rate of 11.6% from 2022 to 2027 [8].

Group 1: Financial Performance - In 2024, the company achieved operating revenue of 1.203 billion (up 14.75%) and net profit attributable to shareholders of 254 million (up 15.95%) [1] - For Q4 2024, operating revenue was 349 million (up 11.51%) and net profit attributable to shareholders was 71 million (up 5.05%) [1] - In Q1 2025, the company reported operating revenue of 225 million (down 0.57%) and net profit attributable to shareholders of 44 million (down 6.54%) [1] Group 2: Plasma Collection and Product Development - In 2024, the company’s nine single plasma collection stations achieved a plasma collection volume of 562 tons (up 8.7%) [2] - The blood products business generated revenue of 1.071 billion (up 8.8%) with a gross margin of 43.04% (up 2.28 percentage points) [2] - The company obtained a drug registration certificate for prothrombin complex in May 2024, expanding its product range to 11 varieties across three categories [2] Group 3: Real Estate and Industry Development - In 2024, the company’s property rental business generated revenue of 121 million (up 250.44%) with a gross margin of 28.5% (up 11.32 percentage points) [3] - The company is developing a life sciences park focusing on synthetic biology and brain science, attracting high-quality enterprises in the biopharmaceutical sector [3] Group 4: Profit Forecast and Investment Recommendation - The company forecasts revenues of 1.288 billion, 1.415 billion, and 1.572 billion for 2025, 2026, and 2027 respectively, with net profits of 278 million, 317 million, and 369 million [4] - The corresponding price-to-earnings ratios are projected to be 23.1, 20.3, and 17.4 [4]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company achieved a revenue of 1.203 billion yuan in 2024, reflecting a growth of 14.75%, with a net profit of 254 million yuan, up by 15.95% [4][9]. - The company’s plasma collection volume increased steadily, reaching 562 tons in 2024, a year-on-year growth of 8.7% [5]. - The life science park is showing significant industrial cluster effects, with rental income from the property business soaring by 250.44% in 2024 [6]. - The company is expected to see revenue growth of 12.88 billion yuan in 2025, with net profits projected at 278 million yuan [7][9]. Company Overview - The latest closing price of the company's stock is 6.72 yuan, with a total market capitalization of 44.6 billion yuan [3]. - The company has a debt-to-asset ratio of 5.0% and a price-to-earnings ratio of 20.36 [3]. Financial Performance - In Q1 2025, the company reported a revenue of 225 million yuan, a slight decrease of 0.57% compared to the previous quarter [4]. - The gross margin for the blood products business was 43.04% in 2024, an increase of 2.28 percentage points [5]. - The company’s earnings per share (EPS) for 2024 was 1.12 yuan, with projections of 1.23 yuan for 2025 [9][12].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002880 证券简称：卫光生物 公告编号：2025-005 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 □是 √否 公司经本次董事会审议通过的利润分配预案为：以226,800,000为基数，向全体股东每10股派发现金红利 2元（含税），送红股0股（含税），不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 公司主要从事血液制品的研发、生产和销售，所处行业为血液制品行业。血液制品是从健康人血液、血 浆或特异免疫人血浆中分离、提纯或由重组DNA技术制备的，用于治疗和预防的蛋白或细胞组分的统 称，主要有白蛋白类、免疫球蛋白类和凝血因子类等三大类产品。血液制品在医疗急救、战争、重大灾 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002880 证券简称:卫光生物 公告编号:2025-008 深圳市卫光生物制品股份有限公司 关于2024年度日常关联交易执行情况及 预计2025年度日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、日常关联交易基本情况 （一）日常关联交易概述 深圳市卫光生物制品股份有限公司（以下简称公司）于2025年4月21日召开第三届董事会第三十二次会 议、第三届监事会第二十五次会议审议通过了《关于2024年度日常关联交易执行情况及预计2025年度日 常关联交易的议案》。 公司及子公司基于实际经营需要，预计2025年与关联方武汉生物制品研究所有限责任公司发生日常关联 交易的金额为100万元，公司2024年实际发生的日常关联交易金额为2.88万元。 根据《深圳证券交易所股票上市规则》《公司章程》等的相关规定，本事项无需提交公司股东大会审 议。 （二）2024年度日常关联交易执行情况 ■ （三）预计2025年度日常关联交易情况 ■ 二、关联方及关联关系 公司名称：武汉生物制品研究所有限责任公司 ...

深圳市卫光生物制品股份有限公司 审 计 报 告 大信审字[2025]第 5-00037 号 深圳市卫光生物制品股份有限公司全体股东： 一、审计意见 大信审字[2025]第 5-00037 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 邮编 100083 网址 Internet： www.daxincpa.com.cn 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 WUYIGE Certified Public Accountants.LLP Room 2206 22/F,Xueyuan International Tower No.1 Zhichun Road,Haidian Dist. Beijing,China,100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 审计报告 我们审计了深圳市卫光生物制品股份有限公司（以下简称"贵公司"）的财务报表，包 括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及 ...

大信会计师事务所（特殊普通合伙） 深圳市卫光生物制品股份有限公司 非经营性资金占用及其他关联资金往 来情况汇总表的专项 审计报告 大信专审字[2025]第 5-00027 号 非经营性资金占用及其他关联资金往来情况汇总表的 专项审计报告 大信专审字[2025]第 5-00027 号 深圳市卫光生物制品股份有限公司全体股东： 我们接受委托，审计了深圳市卫光生物制品股份有限公司（以下简称"贵公司"）的财 务报表，包括 2024 年 12 月 31 日合并及母公司资产负债表、2024 年度合并及母公司利润 表、股东权益变动表、现金流量表以及财务报表附注，并于 2025 年 4 月 21 日出具大信审字 [2025]第 5-00037 号审计报告。在对上述财务报表审计基础上，我们审核了贵公司编制的《上 市公司 2024 年度非经营性资金占用及其他关联资金往来情况汇总表》（以下简称"非经营性 资金占用及其他关联资金往来情况汇总表"）。 一、管理层和治理层的责任 WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 邮编 100083 网址 Internet： www.daxincpa.com ...

深圳市卫光生物制品股份有限公司 2024 年度独立董事述职报告 深圳市卫光生物制品股份有限公司 2024年度独立董事述职报告 （汪新民） 各位股东（股东代表）： 作为深圳市卫光生物制品股份有限公司（以下简称公司）的独立董事，本人 严格按照《公司法》《证券法》《上市公司独立董事管理办法》及《独立董事工 作制度》等规定，依法依规认真履行职责，充分发挥独立董事的作用，切实维护 公司及全体股东的利益。现将 2024 年度本人履行独立董事职责的情况汇报如下： 一、基本情况 本人汪新民，1969 年出生，本科学历，EMBA 学位，注册会计师、注册税 务师，现任公司独立董事，立信会计师事务所(特殊普通合伙)合伙人；曾任天健 会计师事务所高级经理、亚太（集团）会计师事务所合伙人。 作为公司独立董事，经自查，本人符合《上市公司独立董事管理办法》等法 律法规对独立董事独立性的相关要求，不存在影响独立性的情况。 二、独立董事年度履职概况 1.董事会、股东大会履职情况 报告期内，公司共召开 9 次董事会、3 次股东大会。本人均出席了上述会议。 在收到公司发出的相关会议通知后，认真审阅公司议案，及时核实议案相关情况， 积极运用本人的专 ...